VOGLIVIN MG2

bt_bb_section_bottom_section_coverage_image
https://www.larivinpharma.com/wp-content/uploads/2024/04/VOGLIVIN-MG2.jpg

Composition

Active Ingredients:

  • Voglibose 0.2 mg
  • Glimepiride 2 mg
  • Metformin 500 mg

Description:
Voglivin MG2 is a combination tablet designed for the management of type 2 diabetes mellitus. This formulation combines three effective antidiabetic agents—Voglibose, Glimepiride, and Metformin—to provide comprehensive glycemic control by addressing multiple aspects of blood glucose regulation.

Indications:
Voglivin MG2 is indicated for:

  • Management of type 2 diabetes mellitus in adults.
  • Improvement of glycemic control in patients inadequately controlled with Metformin, Glimepiride, or Voglibose alone.
  • As an adjunct to diet and exercise to enhance blood glucose control.

Mechanism of Action:

  • Voglibose: An alpha-glucosidase inhibitor that slows the absorption of carbohydrates in the intestines, reducing postprandial blood glucose levels.
  • Glimepiride: A sulfonylurea that stimulates insulin release from pancreatic beta cells, helping to lower blood glucose levels.
  • Metformin: Reduces hepatic glucose production and enhances insulin sensitivity in peripheral tissues, leading to improved glucose uptake and utilization.

Dosage and Administration:

  • The usual dose is one tablet of Voglivin MG2 daily, taken with the morning meal to minimize gastrointestinal side effects.
  • Dosage adjustments should be made based on individual patient response and blood glucose levels.

Contraindications:

  • Hypersensitivity to Voglibose, Glimepiride, Metformin, or any component of the tablet.
  • Severe renal impairment or significant liver dysfunction.
  • Type 1 diabetes mellitus or diabetic ketoacidosis.
  • Pregnancy and breastfeeding.

Warnings and Precautions:

  • Monitor renal function regularly due to the Metformin component.
  • Caution is advised in patients with a history of gastrointestinal issues, hypoglycemia, or those taking other antidiabetic medications.
  • Discontinue use and consult a healthcare provider if symptoms of lactic acidosis (e.g., unusual muscle pain, difficulty breathing) or severe hypoglycemia occur.

Side Effects:
Common side effects may include:

  • Nausea
  • Diarrhea
  • Abdominal pain
  • Headache

Serious side effects, although rare, may include:

  • Lactic acidosis
  • Severe hypoglycemia
  • Liver dysfunction

Drug Interactions:

  • May interact with other antidiabetic medications, corticosteroids, and diuretics.
  • Caution is advised with drugs affecting glucose metabolism or renal function.

Storage:

  • Store in a cool, dry place, away from direct sunlight.
  • Keep out of reach of children.

Packaging:

  • Available in blister packs of 10 tablets.

Disclaimer:
This information is provided for educational purposes only. For personalized medical advice and treatment options, consult a healthcare professional.

https://www.larivinpharma.com/wp-content/uploads/2020/06/large_blue_triangle_04.png
https://www.larivinpharma.com/wp-content/uploads/2024/04/VOGLIVIN-MG2.jpg
https://www.larivinpharma.com/wp-content/uploads/2020/04/small_blue_triangle.png
https://www.larivinpharma.com/wp-content/uploads/2020/06/large_blue_triangle_01.png
https://www.larivinpharma.com/wp-content/uploads/2023/03/larivin-pharma-footer-icon-160x160.png
No.32, First Floor, Varadharaja Swamy Nagar, Sri Krishna Nagar, Maduravoyal, Chennai, Tamil Nadu 600095

© 2023 Larivin Pharma Private Limited. All rights reserved